Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy


Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year.

The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise.

Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year.

Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet.

Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts.

Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning.

https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff

This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *